Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. by Villani, Alexandra-Chloé et al.
Published in: Nature Genetics (2009) 
Status: Postprint (Author’s version) 
 
 
Common variants in the NLRP3 region contribute to Crohn's disease 
susceptibility 
 
Alexandra-Chloé Villain1,2, Mathieu Lemire3, Geneviève Fortin1, Edouard Louis4, Mark S Silverberg5, Catherine 
Collette1, Nobuyasu Baba6, Cécile Libioulle4, Jacques Belaiche4, Alain Bitton7, Daniel Gaudet8, Albert Cohen9, 
Diane Langelier10, Paul R Fortin11, Joan E Wither11, Marika Sarfati6, Paul Rutgeerts12, John D Rioux13, Séverine 
Vermeire12, Thomas J Hudson3 & Denis Franchimont1,14 
1
 Division of Gastroenterology, McGill University Health Centre, Montreal General Hospital, 1650 Cedar Avenue, Montréal, Québec H3G 
1A4, Canada.  
2McGill University and Génome Québec Innovation Centre, 740 Doctor Penfield Avenue, Montréal, Québec H3A 1A4, Canada.  
3Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College Street, Suite 800, Toronto, Ontario M5G 0A3, Canada. 
4Division of Gastroenterology, CHU, Université de Liège, 13 avenue de l'Hôpital Bât. B35, 4000 Liège, Belgium.  
5Mount Sinai Hospital IBD Centre, University of Toronto, 441-600 University Avenue, Toronto, Ontario M5G 1X5, Canada.  
6lmmunoregulation Laboratory, CHUM Research Center, Université de Montréal, 1560 rue Sherbrooke Est, Montréal, Québec H2L 4M1, 
Canada.  
7Division of Gastroenterology, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Avenue West, Montréal, Québec H3A 
1A1, Canada.  
8Université de Montréal, Centre de médecine génique communautaire de l'Université de Montréal, Hôpital universitaire de Chicoutimi, 555 
boulevard de l'Université, Chicoutimi, Québec G7H 2B1, Canada.  
9Jewish General Hospital, 3755 chemin de la Côte-Sainte-Catherine, Montréal, Québec H3T 1E2, Canada.  
10Centre Hospitalier Universitaire de Sherbrooke-Hôtel-Dieu, 580 rue Bowen Sud, Sherbrooke, Québec J1G 2E8, Canada.  
11Arthritis Centre of Excellence, Toronto Western Hospital Research Institute, 399 Bathurst Street, University of Toronto, Toronto, Ontario 
M5T 2S8, Canada.  
12Department of Gastroenterology, University Hospital Gasthuisberg, 49 Herestraat, 3000 Leuven, Belgium.  
13Université de Montréal and Montréal Heart Institute, Research Center, 5000 rue Bélanger, Montréal, Québec HIT 1C8, Canada.  
14Department of Gastroenterology, Erasme Hospital, ULB, 808 Lennik road, 1070 Brussels, Belgium. 
 
Abstract 
We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on 
chromosome 1q44 downstream of NLRP3 (previously known as CIAS1 and NALP3) that are associated with 
Crohn's disease. The associations were consistently replicated in four sample sets from individuals of European 
descent. In the combined analysis of all samples (710 father-mother-child trios, 239 cases and 107 controls), 
these SNPs were strongly associated with risk of Crohn's disease (Pcombined = 3.49 × 10-9, odds ratio = 1.78, 
confidence interval = 1.47-2.16 for rs10733113), reaching a level consistent with the stringent significance 
thresholds imposed by whole-genome association studies. In addition, we observed significant associations 
between SNPs in the associated regions and NLRP3 expression and IL-1β production. Mutations in NLRP3 are 
known to be responsible for three rare autoinflammatory disorders1,2. These results suggest that the NLRP3 
region is also implicated in the susceptibility of more common inflammatory diseases such as Crohn's disease. 
 
 
Crohn's disease and ulcerative colitis are multigenic and heterogeneous inflammatory bowel diseases of the 
gastrointestinal tract that seem to result from a dysregulated mucosal immune response to bacterial antigens in 
the gut lumen of a genetically susceptible host3. NLRP3 is a member of the CATERPILLER4 family of genes 
encoding proteins that comprise a nucleotide-binding domain and a leucine-rich repeat domain. Cryopyrin, the 
protein encoded by NLRP3, controls the inflammasome, a crucial molecular platform that regulates activation of 
caspase-1 and processing of interleukin (IL)-1β—two key mediators of inflammation2,5,6. The potential 
involvement of NLRP3 in the pathogenesis of more common inflammatory disorders motivated us to conduct an 
in-depth genetic analysis of the NLRP3 region. 
We first assessed the association between 47 SNPs in the NLRP3 region and Crohn's disease risk in 296 trios 
from Leuven University Hospital Gasthuisberg (see Methods, Supplementary Methods and Supplementary Table 
1 online). The major alleles of three tagging SNPs were significantly associated with increased risk of Crohn's 
disease in the Leuven sample set (P = 0.0107 for rs4353135; P = 7.63 × 10-3 for rs4266924; P = 1.68 × 10-3 for 
rs10733113; Fig. 1 and Table 1). These SNPs span a 5.3-kb region and are located 4.7 kb downstream of NLRP3 
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and 1.85 kb upstream of the olfactory receptor gene OR2B11 (Fig. 1). No associations were observed with SNPs 
within the NLRP3 gene, and none of the associated SNPs were in linkage disequilibrium with tagging SNPs 
located in NLRP3 or OR2B11. These preliminary associations pointed to the 5.3-kb region near NLRP3, bounded 
by rs4353135 and rs10733113, as a candidate region contributing to Crohn's disease susceptibility. 
 
Figure 1 Association results for the five Crohn's disease sample sets. Top panel shows SNPs, their positions in 
the genes and the linkage disequilibrium structure between them. SNP names in red were genotyped in the 
second phase of the study, subsequent to the sequencing experiment. Middle panel shows D' in the upper left and 
r
2
 in the lower right, (a-e) Lower panels show results from association analysis of Leuven trios (a), Liège trios 
(b), Liège case-control cohort (c), Québec trios (d) and Toronto trios (e). Pvalues for individual alleles are 
reported in a logarithmic scale on the y axis. Color spectrum represents strength of linkage disequilibrium and 
frequency of the associated alleles. 
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In the second phase of the study, we examined the association of the above three SNPs with risk of Crohn's 
disease in additional samples. Overall, we screened one case-control cohort (Liège) and three familial sample 
sets (Liège, Québec and Toronto; see Methods and Supplementary Methods). We replicated our initial 
significant Crohn's disease associations with the major alleles of tagging SNPs rs4266924 and rsl0733113 in all 
four sample sets (P < 0.05; Fig. 1 and Table 1). For the Québec and Toronto cohorts, the observed  associations 
remained whether the analysis was done with or without samples from individuals of Jewish ancestry (data not 
shown). Association with rs4353135 was replicated only in the Toronto sample set (P < 0.05; Fig. 1 and Table 
1). Combined analysis of all Crohn's disease samples revealed strong associations for rs4353135 (Pcombined = 8.36 
× 10-3, odds ratio = 1.21, confidence interval = 1.05-1.39, T allele frequency = 71% in cases and 65% in 
controls), rs4266924 (Pcombined = 6.01 × 10-7, odds ratio = 1.69, confidence interval = 1.37-2.07, A allele 
frequency = 91% in cases and 84% in controls) and rs10733113 (Pcombined = 3.49 × 10-9, odds ratio = 1.78, 
confidence interval = 1.47-2.16, G allele frequency = 90% in cases and 80% in controls). 
This regional association was the first step in localizing the most likely causal variant(s). Because the observed 
association signal was not in linkage disequilibrium with any genotyped variant within NLRP3, we resequenced 
a 9-kb region extending from the NLRP3 3' UTR to the 5.3-kb  region described above,  inclusively,  which  also  
comprised OR2B11 (Supplementary Table 2 online). Overall, we selected 16 Crohn's disease samples and 8 
controls based on genotypes at markers rs4266924 and rs10733113 to fully define the linkage disequilibrium 
within the region and identify all polymorphisms in linkage disequilibrium with the associated SNPs. The 
resequencing effort identified 79 SNPs, 8 of which were previously genotyped. Among these SNPs, 14 were 
novel compared to dbSNP release 129, and 60 had a minor allele frequency > 0.05 (Supplementary Table 3 
online). 
We next conducted comprehensive genotyping to identify polymorphisms with stronger associations 
(Supplementary Methods). We genotyped a total of 24 SNPs in the Leuven exploratory Crohn's disease trios 
(Supplementary Table 3) and analyzed 15 of them after they passed quality control tests (see Methods). None of 
the SNPs within OR2B11 (Supplementary Table 3) were associated with Crohn's disease. The major alleles of 
three SNPs, spanning a 1.8-kb region bounded by rs4353135 and rs10733113, were associated with Crohn's 
disease (Fig. 1 and Table 1). According to the computational method ESPERR7, two of these SNPs (rs6672995 
and rs55646866) are located in a predicted regulatory region. The third variant, SS107635144, was selected by 
the tagging algorithm8. These SNPs were in high linkage disequilibrium (r2 > 0.70) with rs4266924 and 
rs10733113. None of these three SNPs were tags for the SNPs that were not genotyped in the region. 
We subsequently screened these three variants in the other four sample sets, and their associations were 
consistently replicated (Fig. 1 and Table 1). Combined analysis of all Crohn's disease samples revealed strong 
associations for rs55646866 (Pcombined = 7.2 × 10-7, odds ratio = 1.69, confidence interval = 1.38-2.08, C allele 
frequency = 91% in cases and 84% in controls), rs6672995 (Pcombined = 2.91 × 10-6, odds ratio = 1.53, confidence 
interval = 1.28-1.82, G allele frequency = 87% in cases and 79% in controls) and SS107635144 (Pcombined = 8.50 
× 10-6, odds ratio = 1.53, confidence interval = 1.27-1.84, C allele frequency = 88% in cases and 80% in 
controls). 
Conditioning on one of these associated SNPs to evaluate the residual significance of the others did not provide 
evidence of additive effects of the associated SNPs on the risk. Rather, the association they all showed with 
Crohn's disease can be explained solely by linkage disequilibrium. To account for multiple testing issues, we 
note that if all 62 SNPs had been genotyped in the Leuven exploratory sample in the same study phase, then 
rs55646866 would have reached a significance level (P = 5.72 × 10-4) that, after correction using a permutation 
procedure, would have still been significant (Pcorrected = 0.019, estimated from 5,000 replicates; see Methods). 
This result was further strengthened by the consistent replication of rs55646866 in all studied samples. 
We next evaluated associations between genotype and gene expression to determine whether the above SNP 
associations reflected exacting regulatory effects on NLRP3. We first assessed the influence of the six SNPs 
(Table 1) on NLRP3 mRNA expression from freshly isolated peripheral blood cells (PBCs) and from monocytes 
isolated from the peripheral blood, as NLRP3 is primarily expressed in granulocytes and monocytes9 
(Supplementary Methods). A significant association was observed between NLRP3 expression and rs4353135 
genotypes in PBCs (P = 0.00246; Fig. 2a) and monocytes (P = 0.0124; Fig. 2b), with homozygosity for the risk 
allele being associated with the lowest level of NLRP3 expression. Results for the five other Crohn's disease-
associated SNPs are shown in Supplementary Figure 1 and Table 4 online. 
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Table 1 Replication studies and pooled analysis showing association between SNPs in the 5.3-kb region and risk 













Odds ratio (95% Cl)e P valuee 
Leuven (296 trios) 
rs4353135f T 0.65 0.73 118:82   1.44 (1.08-1.91) 0.0107 
rs4266924f A 0.86 0.91 57:31   1.78 (1.14-2.79) 7.63 × 10-3 
rs55646866g C 0.86 0.93 57:26   2.19 (1.37-3.52) 5.72 × 10-4 
rs6672995g G 0.83 0.88 64:39   1.64 (1.09-2.48) 0.0133 
ss107635144g C 0.84 0.91 64:36   1.78 (1.16-2.73) 4.82 × 10-3 
rs10733113f G 0.84 0.91 65:34   1.91 (1.24-2.95) 1.68 × 10-3 
Liège trios (155 trios) 
rs4353135f T 0.62 0.73 33:20   1.65 (0.93-2.92) 0.0727 
rs4266924f A 0.84 0.94 22:7   3.14 (1.36-7.26) 4.31 × 10-3 
rs55646866g C 0.85 0.95 20:6   3.33 (1.36-8.18) 4.80 × 10-3 
rs6672995g G 0.79 0.89 31:15   2.07 (1.11-3.84) 0.0171 
ss107635144g C 0.80 0.90 27:13   2.08 (1.03-4.18) 0.0253 
rs10733113f G 0.83 0.92 24:10   2.40 (1.16-4.96) 0.0148 
Liège CC (239 Crohn's disease and 107 controls) 
rs4353135f T 0.65 0.65  39:44:11 92:95:27 1.01 (0.71-1.46) 0.944 
rs4266924f A 0.79 0.90  63:35:4 184:41:2 2.43 (1.53-3.85) 1.62 × 10-4 
rs55646866g C 0.80 0.91  66:32:4 191:38:3 2.33 (1.47-3.69) 4.32 × 10-4 
rs6672995g G 0.74 0.86  57:40:7 172:56:4 2.19 (1.46-3.30) 1.87 × 10-4 
ss107635144g C 0.75 0.86  57:38:7 165:56:3 2.13 (1.41-3.23) 3.94 × 10-4 
rsl0733113f G 0.76 0.88  58:38:5 177:47:3 2.36 (1.52-3.65) 1.20 × 10-4 
Québec (130 trios)h 
rs4353135f T 0.67 0.73 68:48   1.42 (1.00-2.01) 0.0627 
rs4266924f A 0.85 0.91 43:26   1.65 (1.02-2.70) 0.0400 
rs55646866g C 0.84 0.90 43:26   1.65 (1.02-2.70) 0.0400 
rs6672995g G 0.78 0.85 53:32   1.66 (1.09-2.52) 0.0220 
ss107635144g C 0.80 0.88 49:28   1.75 (1.12-2.73) 0.0160 
rs10733113f G 0.79 0.89 53:28   1.89 (1.19-3.00) 5.10 × 10-3 
Toronto (129 trios)i 
rs4353135f T 0.62 0.74 63:35   1.80 (1.17-2.77) 4.40 × 10-3 
rs4266924f A 0.82 0.92 39:16   2.50 (1.44-4.35) 1.12 × 10-3 
rs55646866g C 0.83 0.90 36:20   1.80 (1.07-3.04) 0.0313 
rs6672995g G 0.77 0.85 46:28   1.64 (1.05-2.56) 0.0355 
ss107635144g C 0.78 0.88 46:23   2.00 (1.22-3.27) 5.18 × 10-3 
rs10733113f G 0.77 0.91 50:17   3.00 (1.76-5.10) 2.47 × 10-5 
Combined (710 trios, 239 Crohn's disease and 107 controls)j 
rs4353135f T 0.65 0.71 282:185 39:44:11 92:95:27 1.21 (1.05-1.39) 8.36 × 10-3 
rs4266924f A 0.84 0.91 161:80 63:35:4 184:41:2 1.69 (1.37-2.07) 6.01 × 10-7 
rs55646866g C 0.84 0.91 156:78 66:32:4 191:38:3 1.69 (1.38-2.08) 7.20 × 10-7 
rs6672995g G 0.79 0.87 194:114 57:40:7 172:56:4 1.53 (1.28-1.82) 2.91 × 10-6 
ss107635144g C 0.80 0.88 186:100 57:38:7 165:56:3 1.53 (1.27-1.84) 8.50 × 10-6 
rs10733113f G 0.80 0.90 192:89 58:38:5 177:47:3 1.78 (1.47-2.16) 3.49 × 10-9 
 
Because NLRP3 is involved in IL-1β processing, we therefore also evaluated whether these six SNPs influenced 
IL-1β production. We cultured monocytes in the presence or absence of crude lipopoly-saccharide (LPS; 
Supplementary Methods), as its derivatives have been shown to stimulate NLRP3 expression10. We then assessed 
IL-1β levels in culture supernatants. We observed a borderline-significant association between IL-1β levels and 
rs6672995 genotype under the unstimulated condition (P = 0.0502; Fig. 2c) and a significant association under 
the LPS-stimulated condition (P = 0.00591; Fig. 2d). In both cases, homozygosity for the risk allele was 
associated with the lowest level of IL-1β. Results for the five other Crohn's disease-associated SNPs are shown 
in Supplementary Figure 2 and Table 5 online. 
We also examined Nlrp3 expression in colon tissues isolated from mice with trinitrobenzene sulfonic acid 
(TNBS)-induced colitis, a model that mimics Crohn's disease-like intestinal inflammation, and in biopsies from 
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individuals with Crohn's disease. Nlrp3 expression was significantly higher in both acute (fold change = 9.38 ± 
1.58; P < 0.0009) and chronic (fold change = 2.70 ± 0.88; P < 0.0152) TNBS-induced colitis models than in 
colon tissues from control mice (Fig. 2e; see Methods and Supplementary Methods). NLRP3 expression was also 
significantly higher in the ulcerated intestinal mucosa from human Crohn's disease samples (fold change = 4.08 
± 1.33; P < 0.0028) than in healthy controls (Fig. 2f; see Methods and Supplementary Methods). 
 
Figure 2 NLRP3 functional study results. (a,b) Linear regression analysis of NLRP3 mRNA level versus 
rs4353135 genotype in DNA-RNA matched freshly isolated PBCs (a; n = 30) and monocytes (b; n = 31) 
obtained from healthy individuals. Genotypes of the six Crohn's disease (CD)-associated SNPs (Table 1) were 
obtained by sequencing. Mean threshold cycle (Ct) was calculated for each sample from three replicates and 
then used to calculate relative expression level (∆Ct), which is the difference between NLRP3 Ct and endogenous 
control 18S RNA Ct. Fold change in NLRP3 expression was calculated using comparative Ct method (see 
Methods), using as a reference the average ∆Ct of homozygosity for the risk allele. (c,d) Linear regression 
analysis of IL-1β production (pg/ml) versus rs6672995 genotype for unstimulated (c) and LPS-stimulated (d; 1.0 
µg/ml) conditions after 3 h of incubation. ∆Ct (a,b) and IL-1β level (c,d) for each individual are shown in red; 
regression lines are shown as dashed lines (a-d). (e) Quantitative real-time PCR analysis of Nlrp3 expression in 
colons of healthy mice (n = 6), mice with acute TNBS-induced colitis (n = 12) and mice with chronic TNBS-
induced colitis (n = 6). (f) Quantitative real-time PCR analysis of NLRP3 expression in colon specimens from 
healthy individuals (n = 35) and individuals with Crohn's disease (n = 25). Expression was normalized to 18S 
RNA expression; each bar represents mean fold change in NLRP3 expression ± s.e.m. normalized to that of 
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NLRP3 (chromosome 1q44) encodes cryopyrin, which is involved in the inflammasome signaling platform by 
regulating caspase-1 activity and IL-1β processing. The importance of cryopyrin in inflammation is highlighted 
by gain-of-function mutations within its NOD domain that are associated with three hereditary periodic fever 
syndromes: Muckle-Wells syndrome, familial cold autoinflammatory syndrome and neonatal-onset multisystem 
inflammatory disease1,2. Hyperproduction of IL-1β is thought to be a central event leading to symptoms in these 
three syndromes1. Consistent with these observations is the successful use of IL-1β targeted therapy for treating 
Muckle-Wells syndrome11 and familial cold autoinflammatory syndrome12. 
In our study, contrary to the gain-of-function mutations described above leading to hyperproduction of IL-1β, we 
uncovered a regulatory region downstream of NLRP3 that contributes to Crohn's disease susceptibility and is 
associated with hypoproduction of IL-1β and decreased NLRP3 expression. Indeed, the risk allele of rs6672995, 
located in a predicted regulatory region7, was associated with a decrease in LPS-induced IL-1β production, and 
the risk allele of rs4353135 was associated with a decrease in baseline NLRP3 expression in two independent 
sample sets of healthy donors. It is noteworthy that these two SNPs were in weak linkage disequilibrium (r2 < 
0.105) in our combined sample set. Although the causal variant has not been conclusively shown and may still 
be unidentified, it is most likely to be in linkage disequilibrium with the tested variants. Nonetheless, we have 
shown that SNPs in the associated 5.3-kb region influence NLRP3 at both the gene expression and functional 
levels, as indicated by altered NLRP3 expression and IL-1β production. Notably, dysregulated IL-1β production 
has also been linked to Crohn's disease pathogenesis in which the three major NOD2 (chromosome 16q12) 
mutations result in a loss-of-function phenotype, with decreased NF-κB activation in response to muramyl 
dipeptide stimulation and decreased IL-1β production in primary human mononuclear and dendritic cells from 
individuals with Crohn's disease13-16. Our results further support the recent Crohn's disease immunopathogenesis 
paradigm, which suggests that a defective innate immune response impairs clearance of luminal antigens and/or 
pathogens and leads to the development of chronic intestinal inflammation and Crohn's disease. NLRP3 may thus 
have a role in the initiation phase of the disease, as indicated by our in vitro and expression experiments, as well 
as a role in perpetuating chronic inflammation through further activation of caspase-1 and processing of IL-1β, 
as indicated by the enhanced NLRP3 expression in the Crohn's disease and chronic TNBS-induced colitis 
samples. 
The NLRP3 locus can be added to the list of several newly uncovered Crohn's disease loci at which the common 
allele has been reported to be the risk allele17-22. Although it is difficult to strictly distinguish between one allele 
being a susceptibility risk factor and the other being a protective one, estimating attributable fractions and 
prevented fractions in addition to odds ratios offers insight into how to interpret these associations with very 
common risk factors in the context of complex diseases. If the SNPs with the strongest associations from Table 1 
are interpreted as risk factors, then the attributable fractions (that is, the reduction in prevalence if the risk factor 
were removed from the population) of the alleles fall in the range of 45-55%. These proportions of 'cases 
explained' (all other factors being ignored) are large, but not surprisingly so, as most members of the population 
are carriers of the risk factors. Conversely, if the minor alleles are interpreted as protective factors, then their 
prevented fractions (that is, the proportion by which the prevalence would increase if the protective factor were 
removed from the population) fall in the range of 10-14%, a range easier to interpret in the context of complex 
genetic diseases. 
Several recent genome-wide association studies have identified new Crohn's disease susceptibility genes using 
the Illumina HumanHap300 Genotyping BeadChip17-19 and the Affymetrix GeneChip Human Mapping 500K 
Array Set21. Although rs4353135 is present on the Human Mapping 500K Array Set, this SNP showed the 
weakest significance of all six SNPs from Table 1, was the only one not consistently replicated across all 
samples and was in weak linkage disequilibrium with the other SNPs (max r2 = 0.28). Supplementary Table 6 
online shows the linkage disequilibrium between SNPs on the Illumina HumanHap300 and the Affymetrix 
GeneChip Human Mapping 500K arrays that were not genotyped in the present study and the SNPs from Table 1 
found in HapMap. With a maximum r2 of only 0.16, these observations may explain why this region escaped 
detection in these genome-wide association studies. 
A recent meta-analysis of three large genome-wide association studies of Crohn's disease reported that well-
established associations with Crohn's disease account for ~20% of the genetic variance observed in Crohn's 
disease, suggesting that additional genetic contributions have yet to be discovered22. With the exception of 
variations within NOD2 and IL23R, established susceptibility alleles have been reported to have relatively 
modest effects, with odds ratios ranging from 0.7 to 1.7 (ref. 22). Despite the modest contribution of NLRP3 to 
the risk of Crohn's disease, our results strongly implicate NLRP3, a gene with an essential role in regulating the 
inflammasome, as a risk factor for Crohn's disease. Our results also suggest that a gene such as NLRP3 that is 
associated with rare, severe autoinflammatory disorders can also be implicated in the susceptibility of more 
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common inflammatory diseases such as Crohn's disease. 
METHODS 
Subjects. Five sample sets from four different centers, totaling 710 Crohn's disease trios, 239 Crohn's disease 
cases and 107 controls, were assembled for this project (Table 1). All participants gave informed consent, and 
studies were approved by the Institutional Review Board of each institution that sent samples. A clinical subtype 
of Crohn's disease was assigned using standard clinical criteria23,24, except for a few 'indeterminate colitis' cases 
that were excluded from the study (Supplementary Methods). Belgian subjects from Leuven University Hospital 
Gasthuisberg (Leuven) were used for the exploratory experiments (n = 296 trios). The replication cohorts 
consisted of Belgian subjects from Université de Liège and of two Canadian cohorts (Québec and Toronto). 
Samples from Liège were subdivided into a family-based cohort (155 Liège trios) and a case-control cohort 
(Liège case-control, 239 Crohn's disease and 107 controls). The Québec cohort (n = 130 trios) comprised 
subjects from multiple sites in the province of Québec and included 22 probands of Ashkenazi and 5 of 
Sephardic Jewish ancestry. The Toronto samples (n = 129 trios) were collected from multiple sites in Toronto 
and included 26 probands of Ashkenazi Jewish ancestry. All study participants were of European descent except 
for 15 probands from Toronto that were excluded from the analyses. 
Genotyping. We first investigated a 67.8-kb region spanning 1q44 (243890897-243958709; NCBI build 35, 
hg17), including NLRP3 (32.9 kb). SNP selection details are given in Supplementary Methods. Samples were 
genotyped using the SNPstream ultra-high-throughput genotyping system (Orchid Biosciences)25 and Sequenom 
homogenous MassExtend (hME) assays (matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry)26. Primers and probes are available in Supplementary Table 1. Analysis was restricted to SNPs 
passing quality filters, excluding SNPs with success rate < 95%, minor allele frequency < 5% or deviation from 
Hardy-Weinberg equilibrium (P < 0.01). Measures of linkage disequilibrium between SNPs and departures from 
Hardy-Weinberg equilibrium were computed using Haploview v4.0 (ref. 27). Families showing mendelian errors 
in 5% or more of the markers were excluded from the analysis (25 Crohn's disease families). 
Sequencing. Primers were designed to have a Tm of 60 °C using the Primer3 program (Supplementary Table 2). 
PCR reactions were done using Hot Start Taq polymerase (Qiagen) in an 8-µl final volume comprising 9 ng of 
DNA (one cycle of 96 °C for 10 min; 40 cycles of 95 °C for 30 s, 58 °C for 1 min and 72 °C for 35 s; and one 
cycle of 72 °C for 7 min). Sequencing was done on an ABI 3730 DNA sequencer (Applied Biosystems) 
according to standard protocols. Sequence traces were assembled and analyzed using the PolyPhred software 
package and were compared to annotated sequences from NCBI build 35, hg17. 
Statistical analysis. Tests of association were done using the likelihood methods implemented in UNPHASED 
v3.0.10 (ref. 28), which can analyze samples of nuclear families, unrelated subjects or a combination of both. For 
nuclear families (cases and their parents), the likelihood is equivalent to the conditional likelihood models on 
which the transmission disequilibrium test is based29. For samples of unrelated cases and controls, the likelihood 
is equivalent to a logistic model, which allows estimations of risk effects in terms of odds ratios along with their 
confidence intervals. It also allows conditioning on the observed association at one marker, to test whether or not 
the observed significance at others can solely be explained by linkage disequilibrium. A permutation procedure 
is implemented to allow the calculation of significance levels that are corrected for the number of tests. 
Attributable and prevented fractions were calculated under the assumption that alleles had additive effects on the 
penetrance scale, that odds ratios from Table 1 are good approximations for the relative risks and that allele 
frequencies in the controls are reasonable estimates of population frequencies. 
RNA extraction and quantitative real-time PCR. Details on tissue collection and monocyte isolation are given 
in Supplementary Methods. Biopsies preserved in RNAlater (Qiagen) were homogenized, and total RNA was 
extracted using TRIzol (Invitrogen). Total RNA was extracted from monocytes using an RNeasy kit (Qiagen). 
Total RNA was extracted from PBCs using a PAXgene blood RNA kit (Qiagen) with RNase inhibitor, using off-
column DNase I digestion and ethanol precipitation to improve RNA yield and quality. First-strand cDNA was 
synthesized from 1 µg of RNA template with a cDNA archive kit (Applied Biosystems), using MultiScribe 
reverse transcriptase and random primers. Quantitative real-time PCR assays (mouse Nlrp3, Mm00840904_ml; 
human NLRP3, Hs00918082_ml; 18S RNA, 4319413E; Applied Biosystems) were conducted using an ABI 
PRISM 7900 sequence detection system based on the 5' nuclease assay30 and quantified using Applied 
Biosystems' comparative threshold cycle (Ct) method. The Wilcoxon signed-rank test was used to evaluate tissue 
(mouse and human) expression differences. Associations between NLRP3 expression or IL-1β level and the 
genotypes of the Crohn's disease-associated SNPs were assessed using linear regression. Analyses were done 
using GraphPad Software. 
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DNA extraction. Monocyte DNA was isolated from whole blood using a FlexiGene DNA kit (Qiagen). PBC 
DNA was isolated using a Gentra Autopure automated system (Qiagen) according to the manufacturer's protocol. 
Enzyme-linked immunosorbent assay. IL-1β was quantified in monocyte culture supernatants using a human 
IL-1β DuoSet ELISA kit (R&D Systems) according to the manufacturer's protocol. 
URLs. ESPERR software, http://www.bx.psu.edu/projects/esperr. 
Accession codes. GenBank: NLRP3, AF054176; OR2B11, NM_001004492. OMIM: NLRP3, 606416; OR2B11, 
605956. SNP data have been submitted to NCBI dbSNP under the numbers ss107635120, ss107635122, 
ss107635124, SS107635126, ss107635128, ss107635130, ss107635132, ss107635133, SS107635136, 
ss107635138, ss107635140, ss107635142, ss107635144, SS107635146. 
Note: Supplementary information is available on the Nature Genetics website. 
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